Bill
S 6523
Overview: S 6523, Requires insurance companies to reimburse all health care practitioners at the same rate for cervical cytology screeningPurpose and Intent: This bill aims to addr
Overview: S 6523, Requires insurance companies to reimburse all health care practitioners at the same rate for cervical cytology screening
Purpose and Intent: This bill aims to address disparities in reimbursement rates for cervical cytology screening (Pap tests) among different types of healthcare practitioners. The goal is to ensure that all qualified providers, including physicians, nurse practitioners, and physician assistants, are reimbursed at the same rate for performing this important preventive health service.
Key Provisions:
- Requires insurance companies to reimburse all licensed healthcare practitioners at the same rate for cervical cytology screening
- Prohibits insurance companies from discriminating in reimbursement rates based on the type of provider
- Applies to all private and public health insurance plans operating in the state
Affected Parties and Impacts:
- Patients will have greater access to cervical cancer screening services from a wider range of qualified providers
- Healthcare practitioners, especially nurse practitioners and physician assistants, will benefit from equitable reimbursement
- Insurance companies will need to adjust their billing and reimbursement policies to comply with the new requirements
Procedural and Timeline Considerations:
- The bill has been referred to the Senate Insurance Committee for further review and consideration
- If passed, the new reimbursement requirements would take effect 6 months after the bill becomes law
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
